Everolimus in Treating Patients With Stage IV Melanoma

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed malignant melanoma for which no known standard or potentially curative therapy exists or has been proven to extend life expectancy
• * Stage IV disease
• Measurable disease
• * At least 1 lesion ≥ 20 mm by CT scan or MRI OR ≥ 10 mm by spiral CT scan
• No intracranial disease
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• ECOG 0-2
• Life expectancy
• At least 12 weeks
• Hematopoietic
• Absolute neutrophil count ≥ 1,500/mm\^3
• Platelet count ≥ 100,000/mm\^3
• Hemoglobin ≥ 9.0 g/dL
• No bleeding diathesis
• Hepatic
• AST ≤ 3 times upper limit of normal (ULN)
• Alkaline phosphatase ≤ 3 ULN
• INR ≤ 1.5
• Renal
• Creatinine ≤ 1.5 times ULN
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• Willing to refrain from foods high in fat content
• No uncontrolled infection
• No immunosuppression from any cause (e.g., known HIV infection)
• No other malignancy within the past 5 years except basal cell or squamous cell skin cancer treated with local resection only
• No other severe condition that would preclude study participation or compliance
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• More than 4 weeks since prior immunotherapy or biologic therapy
• Chemotherapy
• More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
• No prior sirolimus or its analogues for any indication
• No other concurrent chemotherapy
• Endocrine therapy
• No concurrent steroids
• Radiotherapy
• More than 4 weeks since prior radiotherapy to head and neck area
• More than 4 weeks since prior radiosurgery
• No prior radiotherapy to \> 30% of bone marrow
• No concurrent radiotherapy
• Surgery
• Not specified
• Other
• At least 1 week since prior and no concurrent CYP3A4 inducers
• No concurrent warfarin
• No concurrent cytotoxic agents
• No other concurrent experimental drugs
• No other concurrent immunosuppressive therapy